Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Though female representation on ASCO panels is increasing, women remain underrepresented on certain panels, and all-male panels still exist.
US medical oncologists may lack understanding of biosimilars and have limited access to education about these products, a survey suggests.
Using telehealth saved cancer patients an estimated $147.40 to $186.10 per visit, as well as 1.2 hours of in-clinic time and 2.9 hours of roundtrip driving time.
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
